Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF Total Revenue

As of the most recent data (June 2026), GERM shows a total revenue of $2.4B. That compares with $1.8B in the prior-year period — up 34.0% year over year. That is above the sector sector average of $1.3B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GERM's total revenue is now $2.4B (was $1.8B) — a 34.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF is outperforming or lagging.

The its sector sector average total revenue is about $1.3B. Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF is at $2.4B, which is higher that average. That is roughly 77.0% above the sector mean. Use the comparison chart on this page to see how GERM stacks up against individual peers as well.

Tracking GERM's total revenue over time shows whether Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF is scaling, shrinking, or reshaping that part of the business. The current reading is $2.4B That compares with $1.8B in the prior-year period — up 34.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total revenue page, Stockcircle has Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $2.4B) with ownership activity and broader fundamentals.